Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma

Journal of Clinical Pathology

Volumn 65, Issue 5, 2012, Pages 399-402

  Yasuoka, Hironao ^a   Tsujimoto, Masahiko ^b   Inagaki, Michiya ^a   Kodama, Rieko ^a   Tsuji, Hiromi ^a   Iwahashi, Yoshifumi ^a   Mabuchi, Yasushi ^a   Ino, Kazuhiko ^a   Sanke, Tokio ^a   Nakamura, Yasushi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; EZRIN; KI 67 ANTIGEN; PODOCALYXIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UTERINE ENDOMETRIOID ADENOCARCINOMA; UTERUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; RECEPTORS, ESTROGEN; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 84860761838     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200359     Document Type: Article

References (18)

1. Sizemore S, Cicek M, Sizemore N, et al. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 2007;67:6183-91. (Pubitemid 47037499)
2. Casey G, Neville PJ, Liu X, et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 2006;15:735-41. (Pubitemid 43264698)
3. Riccioni R, Calzolari A, Biffoni M, et al. Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis 2006;37:218-25. (Pubitemid 44716718)
4. Kelley TW, Huntsman D, McNagny KM, et al. Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 2005;124:134-42. (Pubitemid 40944386)
5. Yasuoka H, Tsujimoto M, Hirokawa M, et al. Podocalyxin expression in undifferentiated thyroid carcinomas. J Clin Pathol 2008;61:1228-9.
6. Hsu YH, Lin WL, Hou YT, et al. Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 2010;176:3050-61.
7. Somasiri A, Nielsen JS, Makretsov N, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 2004;64:5068-73. (Pubitemid 39006520)
8. Furutani Y, Matsuno H, Kawasaki M, et al. Interaction between telencephalin and ERM family proteins mediates dendritic filopodia formation. J Neurosci 2007;27:8866-76. (Pubitemid 47292762)
9. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6. (Pubitemid 38524889)
10. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-81. (Pubitemid 38524888)
11. Elliott BE, Meens JA, SenGupta SK, et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005;7:R365-73.
12. Leonard P, Sharp T, Henderson S, et al. Gene expression array profile of human osteosarcoma. Br J Cancer 2003;89:2284-8. (Pubitemid 38168012)
13. Makitie T, Carpen O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 2001;42:2442-9. (Pubitemid 32954846)
14. Ohtani K, Sakamoto H, Rutherford T, et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002;179:79-86. (Pubitemid 34195656)
15. Kobel M, Langhammer T, Huttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 2006;19:581-7.
16. Kodama S, Kase H, Tanaka K, et al. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 1996;53:23-30. (Pubitemid 26108557)
17. Markova I, Duskova M, Lubusky M, et al. Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer 2010;20:576-82.
18. Fukaya Y, Ishiguro N, Senga T, et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep 2005;14:847-52.